GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alembic Pharmaceuticals Ltd (BOM:533573) » Definitions » Net Interest Income

Alembic Pharmaceuticals (BOM:533573) Net Interest Income : ₹-529 Mil (TTM As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Alembic Pharmaceuticals Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Alembic Pharmaceuticals's net interest income for the three months ended in Jun. 2024 was ₹-132 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2024 was ₹-529 Mil.

Alembic Pharmaceuticals Net Interest Income Historical Data

The historical data trend for Alembic Pharmaceuticals's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alembic Pharmaceuticals Net Interest Income Chart

Alembic Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -254.30 -144.40 -160.00 -498.40 -541.00

Alembic Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.90 -156.90 -151.70 -88.50 -131.80

Alembic Pharmaceuticals Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-529 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alembic Pharmaceuticals Net Interest Income Related Terms

Thank you for viewing the detailed overview of Alembic Pharmaceuticals's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Alembic Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alembic Pharmaceuticals Ltd (BOM:533573) » Definitions » Net Interest Income
Comparable Companies
BOM:543064 BOM:524816 BOM:543635 BOM:506820 BOM:540596 BOM:540222 BOM:500126 BOM:532296 BOM:532482 BOM:506943 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
APLLTD:India
Address
Alembic Road, Vadodara, GJ, IND, 390 003
Website
https://www.alembicpharmaceuticals.com
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Alembic Pharmaceuticals Headlines

No Headlines